Pharmaceutical Industry Reports Rivaroxaban market | Page 2

REPORT DESCRIPTION
Rivaroxaban Market – Overview
Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto.
Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and
potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer
and is being jointly developed with Janssen Research & Development, LLC.
Xarelto is approved for indications such as stroke prevention in non-valvular atrial fibrillation, pulmonary
embolism, deep vein thrombosis, prevention of recurrent venous thromboembolism (VTE), prevention of VTE
after elective hip and knee replacement surgery, and secondary prevention after acute coronary syndrome.
In September 2008, the drug received CE approval for venous thromboembolism in adults undergoing knee and
hip replacement surgeries and in 2011, it was approved by the U.S. Food and Drug Administration (FDA) for the
same indication. Xarelto is approved in over 130 countries by respective regulatory bodies.